Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.

Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, Coppolino A, Kusztos AE, Johnson ME, Chen K, Haddad EA, Fanikos J, Harrington DP, Camp PC, Baden LR; DONATE HCV Trial Team.

N Engl J Med. 2019 Apr 25;380(17):1606-1617. doi: 10.1056/NEJMoa1812406. Epub 2019 Apr 3.

PMID:
30946553
2.

Drug formulary decision-making: Ethnographic study of 3 pharmacy and therapeutics committees.

Schiff GD, Tripathi JB, Galanter W, Paek JL, Pontikes P, Fanikos J, Matta L, Lambert BL.

Am J Health Syst Pharm. 2019 Mar 27. pii: zxz022. doi: 10.1093/ajhp/zxz022. [Epub ahead of print]

PMID:
30915453
3.

"Inactive" ingredients in oral medications.

Reker D, Blum SM, Steiger C, Anger KE, Sommer JM, Fanikos J, Traverso G.

Sci Transl Med. 2019 Mar 13;11(483). pii: eaau6753. doi: 10.1126/scitranslmed.aau6753. Review.

PMID:
30867323
4.

Use of Direct Oral Anticoagulants Among Patients With Limited Income and Resources.

Ting C, Fanikos C, Fatani N, Buckley LF, Fanikos J.

J Am Coll Cardiol. 2019 Feb 5;73(4):526-528. doi: 10.1016/j.jacc.2018.11.024. No abstract available.

PMID:
30704585
5.

Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.

Chopard R, Piazza G, Hurwitz S, Fanikos J, Goldhaber SZ.

J Thromb Thrombolysis. 2019 Feb;47(2):331-335. doi: 10.1007/s11239-018-1767-2.

PMID:
30449000
6.

NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Gundabolu K, Hendrie P, Lee AI, Lee JT, Mann J, McMahon B, Millenson MM, Morton C, Ortel TL, Ozair S, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Williams E, Zakarija A, Hammond L, Dwyer MA, Engh AM.

J Natl Compr Canc Netw. 2018 Nov;16(11):1289-1303. doi: 10.6004/jnccn.2018.0084.

PMID:
30442731
7.

Novel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease.

Buckley LF, Carbone S, Aldemerdash A, Fatani N, Fanikos J.

Am J Med. 2019 Jan;132(1):16-24. doi: 10.1016/j.amjmed.2018.08.019. Epub 2018 Sep 7. Review.

PMID:
30201240
8.

Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety.

Sivashanker K, Fanikos J, Kachalia A.

J Gen Intern Med. 2018 Nov;33(11):2005-2007. doi: 10.1007/s11606-018-4548-x. Epub 2018 Aug 8.

PMID:
30091120
9.

Expanding anticoagulation management services to include direct oral anticoagulants.

Sylvester KW, Ting C, Lewin A, Collins P, Fanikos J, Goldhaber SZ, Connors JM.

J Thromb Thrombolysis. 2018 Feb;45(2):274-280. doi: 10.1007/s11239-017-1602-1. Review.

PMID:
29274044
10.

Fibrinolytic and Anticoagulation Therapy in Patients Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis for Pulmonary Embolism.

Terry KJ, Buckley LF, Aldemerdash A, Fanikos J, Dell'Orfano H.

Cardiovasc Hematol Disord Drug Targets. 2017;17(2):132-135. doi: 10.2174/1871529X17666170908110328.

PMID:
28891451
11.

The Reply.

Barra ME, Fanikos J.

Am J Med. 2017 Aug;130(8):e365-e366. doi: 10.1016/j.amjmed.2017.03.051. No abstract available.

PMID:
28734382
12.

Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism.

Fanikos J, Burnett AE, Mahan CE, Dobesh PP.

Am J Med. 2017 Oct;130(10):1137-1143. doi: 10.1016/j.amjmed.2017.06.004. Epub 2017 Jul 4. Review.

PMID:
28687262
13.

Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.

Fanikos J, Burnett AE, Mahan CE, Dobesh PP.

Am J Med. 2017 Sep;130(9):1015-1023. doi: 10.1016/j.amjmed.2017.04.015. Epub 2017 May 11. Review.

14.

An assessment of currently available i.v. push medication delivery systems.

Fanikos J, Burger M, Canada T, Ebright P, Fleming J, Harder KA, Pham JC, Sawyer MD, Stevenson JG.

Am J Health Syst Pharm. 2017 May 1;74(9):e230-e235. doi: 10.2146/ajhp150830. No abstract available. Erratum in: Am J Health Syst Pharm. 2017 Jul 1;74(13):954.

PMID:
28438828
15.

Best Practices for Medication Utilization Evaluations in Postsurgical Pain Management.

Faley B, Fanikos J.

Curr Emerg Hosp Med Rep. 2017;5(1):33-40. doi: 10.1007/s40138-016-0121-2. Epub 2016 Dec 10. Review.

16.

Review of Nonformulary Medication Approvals in an Academic Medical Center.

Her QL, Amato MG, Seger DL, Gilmore JF, Fanikos J, Fiskio JM, Bates DW.

Jt Comm J Qual Patient Saf. 2017 Feb;43(2):89-96. doi: 10.1016/j.jcjq.2016.10.003. Epub 2016 Oct 13.

PMID:
28334567
17.

Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?

Dobesh PP, Fanikos J.

J Atr Fibrillation. 2016 Aug 31;9(2):1481. doi: 10.4022/jafib.1481. eCollection 2016 Aug-Sep. Review.

18.

Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.

Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ.

Am J Med. 2016 Nov;129(11):1198-1204. doi: 10.1016/j.amjmed.2016.05.041. Epub 2016 Jun 21.

19.

Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age.

Buckley LF, Rybak E, Aldemerdash A, Cheng JW, Fanikos J.

Clin Cardiol. 2017 Jan;40(1):46-52. doi: 10.1002/clc.22591. Epub 2016 Oct 7. Review.

20.

Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.

Huisman MV, Fanikos J.

Am J Emerg Med. 2016 Nov;34(11S):46-51. doi: 10.1016/j.ajem.2016.09.053. Epub 2016 Sep 28. Review.

21.

Regulatory Impact on Thrombosis Treatment, Prevention, and Anticoagulant Use.

Dannemiller R, Ward T, Fanikos J.

Hematol Oncol Clin North Am. 2016 Oct;30(5):1115-35. doi: 10.1016/j.hoc.2016.06.003. Epub 2016 Jul 27. Review.

PMID:
27637311
22.

Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.

Huisman MV, Fanikos J.

Am J Med. 2016 Nov;129(11S):S89-S96. doi: 10.1016/j.amjmed.2016.06.010. Epub 2016 Aug 26. Review.

23.

Bridging Experience With Eptifibatide After Stent Implantation.

Barra ME, Fanikos J, Gerhard-Herman MD, Bhatt DL.

Crit Pathw Cardiol. 2016 Sep;15(3):82-8. doi: 10.1097/HPC.0000000000000084.

PMID:
27465001
24.

A Comparison of Drug Shortages in the Hospital Setting in the United States and Saudi Arabia: An Exploratory Analysis.

Alsheikh M, Seoane-Vazquez E, Rittenhouse B, Fox ER, Fanikos J.

Hosp Pharm. 2016 May;51(5):370-5. doi: 10.1310/hpj5105-370.

25.

Reversal agents for use with direct and indirect anticoagulants.

Smythe MA, Trujillo T, Fanikos J.

Am J Health Syst Pharm. 2016 May 15;73(10 Suppl 2):S27-48. doi: 10.2146/ajhp150959. Review.

PMID:
27147456
26.

Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.

Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A.

J Thromb Thrombolysis. 2016 Aug;42(2):296-311.

27.

North American Thrombosis Forum, AF Action Initiative Consensus Document.

Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, Lopes RD, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI.

Am J Med. 2016 May;129(5 Suppl):S1-S29. doi: 10.1016/j.amjmed.2016.02.001.

PMID:
27126598
28.

The frequency of inappropriate nonformulary medication alert overrides in the inpatient setting.

Her QL, Amato MG, Seger DL, Beeler PE, Slight SP, Dalleur O, Dykes PC, Gilmore JF, Fanikos J, Fiskio JM, Bates DW.

J Am Med Inform Assoc. 2016 Sep;23(5):924-33. doi: 10.1093/jamia/ocv181. Epub 2016 Mar 21.

29.

Patient-reported Outcomes from A National, Prospective, Observational Study of Emergency Department Acute Pain Management With an Intranasal Nonsteroidal Anti-inflammatory Drug, Opioids, or Both.

Pollack CV Jr, Diercks DB, Thomas SH, Shapiro NI, Fanikos J, Mace SE, Rafique Z, Todd KH.

Acad Emerg Med. 2016 Mar;23(3):331-41. doi: 10.1111/acem.12902.

30.

Pharmacology of anticoagulants used in the treatment of venous thromboembolism.

Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A.

J Thromb Thrombolysis. 2016 Jan;41(1):15-31. doi: 10.1007/s11239-015-1314-3. Review. Erratum in: J Thromb Thrombolysis. 2016 Aug;42(2):296-311.

31.
32.

Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.

Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Hendrie P, Kuderer N, Lee A, Lee JT, Lovrincevic M, Millenson MM, Neff AT, Ortel TL, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Yee GC, Zakarija A, McMillian N, Engh AM.

J Natl Compr Canc Netw. 2015 Sep;13(9):1079-95.

PMID:
26358792
33.

Evaluation of a multi-target direct thrombin inhibitor dosing and titration guideline for patients with suspected heparin-induced thrombocytopenia.

Gilmore JF, Adams CD, Blum RM, Fanikos J, Anne Hirning B, Matta L.

Am J Hematol. 2015 Aug;90(8):E143-5. doi: 10.1002/ajh.24042. No abstract available.

34.

Regulatory, legislative, and policy updates with anticoagulant use.

Fanikos J, Buckley LF, Aldemerdash A, Terry KJ, Piazza G, Connors JM, Goldhaber SZ.

J Thromb Thrombolysis. 2015 Apr;39(3):273-87. doi: 10.1007/s11239-015-1198-2. Review.

PMID:
25749940
35.

Medication use evaluation: pharmacist rubric for performance improvement.

Fanikos J, Jenkins KL, Piazza G, Connors J, Goldhaber SZ.

Pharmacotherapy. 2014 Dec;34 Suppl 1:5S-13S. doi: 10.1002/phar.1506. Review.

PMID:
25521847
36.

New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.

Dobesh PP, Fanikos J.

Drugs. 2014 Nov;74(17):2015-32. doi: 10.1007/s40265-014-0301-x. Review.

37.

Consultant's Playbook: A Survey of Pharmacy Consultant Experiences Among Hospitals In the University HealthSystem Consortium.

Hicks D, McCarthy B Jr, Fanikos J, Emamifar A, Nedved A, Thompson B, Bender F, McMahon P.

P T. 2013 Oct;38(10):628-32.

38.

Venous thromboembolic disease.

Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogerty AE, Gao S, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Siddiqi T, Smith JL, Yee GC, Zakarija A, McMillian N, Naganuma M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Nov;11(11):1402-29.

PMID:
24225973
39.

Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.

Fanikos J.

J Med Econ. 2013 Oct;16(10):1190-2. doi: 10.3111/13696998.2013.831353. Epub 2013 Aug 23. No abstract available.

PMID:
23919663
40.

Impact of an immunoglobulin G-specific enzyme-linked immunosorbent assay on the management of heparin-induced thrombocytopenia.

Sylvester KW, Fanikos J, Anger KE, Matta L, Southard RA, Beik N, Lemire SJ, Dorfman DM, Berliner N.

Pharmacotherapy. 2013 Nov;33(11):1191-8. doi: 10.1002/phar.1322. Epub 2013 Jun 27.

PMID:
23813781
41.

Rivaroxaban: practical considerations for ensuring safety and efficacy.

Smythe MA, Fanikos J, Gulseth MP, Wittkowsky AK, Spinler SA, Dager WE, Nutescu EA.

Pharmacotherapy. 2013 Nov;33(11):1223-45. doi: 10.1002/phar.1289. Epub 2013 May 26. Review.

PMID:
23712587
42.

Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.

Alquwaizani M, Buckley L, Adams C, Fanikos J.

Curr Emerg Hosp Med Rep. 2013 Apr 21;1(2):83-97. Print 2013 Jun.

43.

Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.

Atay JK, Fanikos J, Barnes GD, Ehle M, Coatney J, Piazza G, Froehlich JB, Goldhaber SZ.

Am J Cardiol. 2013 Aug 1;112(3):387-9. doi: 10.1016/j.amjcard.2013.03.046. Epub 2013 May 3.

PMID:
23647794
44.

Improving anticoagulation management in patients with atrial fibrillation.

Fanikos JR, Atay JK, Connors JM.

P T. 2013 Mar;38(3):173-7.

45.

Venous thromboembolism in hospitalized patients with active cancer.

Piazza G, Rao AF, Nguyen TN, Seger AC, Hohlfelder B, Fanikos J, Goldhaber SZ.

Clin Appl Thromb Hemost. 2013 Sep;19(5):469-75. doi: 10.1177/1076029613481844. Epub 2013 Mar 11.

PMID:
23482721
46.

Hospital costs of acute pulmonary embolism.

Fanikos J, Rao A, Seger AC, Carter D, Piazza G, Goldhaber SZ.

Am J Med. 2013 Feb;126(2):127-32. doi: 10.1016/j.amjmed.2012.07.025.

PMID:
23331440
47.

Rivaroxaban to prevent pulmonary embolism after hip or knee replacement.

Cios D, Fanikos J.

Circulation. 2012 Apr 10;125(14):e542-4. doi: 10.1161/CIRCULATIONAHA.111.087718. No abstract available.

PMID:
22492951
48.

Patient education program for venous thromboembolism prevention in hospitalized patients.

Piazza G, Nguyen TN, Morrison R, Cios D, Hohlfelder B, Fanikos J, Paterno MD, Goldhaber SZ.

Am J Med. 2012 Mar;125(3):258-64. doi: 10.1016/j.amjmed.2011.09.012.

PMID:
22340923
49.

Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.

Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA.

Pharmacotherapy. 2011 Dec;31(12):1232-49. doi: 10.1592/phco.31.12.1232. Review.

PMID:
22122184
50.

Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.

Fanikos J, Rao A, Seger AC, Piazza G, Catapane E, Chen X, Goldhaber SZ.

Am J Med. 2011 Dec;124(12):1143-50. doi: 10.1016/j.amjmed.2011.07.031.

PMID:
22114828

Supplemental Content

Loading ...
Support Center